Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 3/20 | 0.49 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | ARG1 | P05089 | 1/20 | 0.46 |
| ▸ | ARG2 | P78540 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 2/20 | 0.37 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL210387 | 1.00 | NOS2 (0.49) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL210388 | 1.00 | NOS2 (0.49) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL4223447 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL29401714 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL4223453 | 0.98 | NOS2 (0.47) | NOS2NOS1NOS3ARG1ARG2 | |
| Trifluoroacetic Acid SCHEMBL9659589 | 0.90 | NOS2 (0.42) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL8894370 | 0.85 | NOS2 (0.38) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL1679688 | 0.84 | ARG1 (0.48) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL1679691 | 0.84 | ARG1 (0.48) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL11717051 | 0.84 | NOS2 (0.45) | NOS2NOS1NOS3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441765-B2 | Peptides and medical uses thereof | ANBITION S.R.L. (IT) | 2025-10-14 | — | — | US | disclosed |
| EP-4430064-A1 | CYCLIC PEPTIDE COMPOUNDS WHICH ARE KISS1R RECEPTOR AGONISTS, AND THERAPEUTIC USES THEREOF | Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (FR) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023083815-A1 | CYCLIC PEPTIDE COMPOUNDS WHICH ARE KISS1R RECEPTOR AGONISTS, AND THERAPEUTIC USES THEREOF | INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE L'ALIMENTATION ET L'ENVIRONNEMENT (FR) | 2023-05-19 | — | — | WO | disclosed |
| US-20220064216-A1 | PEPTIDES AND MEDICAL USES THEREOF | ANBITION S.R.L. (IT) | 2022-03-03 | — | — | US | disclosed |
| US-7632951-B2 | Inhibitors of integrin ανβ6 | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-12-15 | — | — | US | disclosed |
| US-7560227-B2 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1377540-B1 | INHIBITORS OF INTEGRIN ALPHA-V-BETA-6 | MERCK PATENT GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006093973-A2 | BIOMARKERS OF VULNERABLE A THEROSCLEROTIC PLAQUES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2005100382-A1 | VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM | BLM GROUP, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050222040-A1 | Vertebrate peptide modulators of lipid metabolism | BLM GROUP, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1377540-A1 | INHIBITORS OF INTEGRIN AvB6 | MERCK PATENT GmbH (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074730-A1 | INHIBITORS OF INTEGRIN αvβ¿6? | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
| US-5580953-A | USEFUL IN THERAPY OF TYPE 2 DIABETES MELLITUS, IMPAIRED GLUCOSE TOLERANCE, OBESITY AND INSULIN RESISTANCE | AMYLIN PHARMACEUTICALS, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| WO-1993010147-A1 | NOVEL AMYLIN ANTAGONIST PEPTIDES AND USES THEREFOR | AMYLIN PHARMACEUTICALS, INC. (US) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441765-B2 | Peptides and medical uses thereof | FLT1, FLT4, TEK | NOS2 322/4885NOS1 186/4885NOS3 225/4885 |
| US-20070207507-A1 | Biomarkers of vulnerable atherosclerotic plaques and methods of use | CD68, APOB, FABP3 | NOS2 2930/4885NOS1 2743/4885NOS3 2590/4885 |
| US-20220064216-A1 | PEPTIDES AND MEDICAL USES THEREOF | FLT1, FLT4, TEK | NOS2 322/4885NOS1 186/4885NOS3 225/4885 |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | ITGB6, ITGB1, ITGA1 | NOS2 4677/4885NOS1 3863/4885NOS3 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.